BioWorld

Sep. 2, 2004

MGI's 'Great Day': Deal To Market Dacogen, Two Companies Bought

MGI Pharma Inc.'s stock surged nearly 20 percent Wednesday after it announced a marketing deal for SuperGen Inc.'s Dacogen, as well as its plans to acquire two private companies focused on oncology. (BioWorld Today) Read More

Forest's Second Alzheimer's Drug Fails In Early Phase III

Gothenburg Biotech Research Focuses On Tools, Stem Cells

MDS Paying Applied Biosystems $40M For MALDI Product Line IP

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 22, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...